Topic Menu
► Topic MenuTopic Editors




2. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Università degli Studi di Genova, 16132 Genova, Italy

Cystic Fibrosis
Topic Information
Dear Colleagues,
Cystic fibrosis (CF) is caused by loss-of-function mutations in the CFTR gene, which encodes for the CFTR chloride/bicarbonate channel. These mutations may have pleiotropic effects on the CFTR protein, including processing disruption of, and stability at, the plasma membrane (PM) and chloride channel activity. Over the last decade, novel drugs, called modulators, have been developed to rescue the basic defect caused by specific mutations. Because of this complex disease etiology, a combination of CFTR modulators is generally required to rescue the trafficking and functional defects of disease-associated CFTR variants. Due to these disease-modifying treatments, unprecedented clinical results have been achieved in people with eligible CF genotypes. However, real-world data show that there are still a considerable number of people with CF, with covered mutations, who may benefit from alternative modulator therapies. These unconventional candidates may address heterogeneity in patient response, as well as promoting increased market competition and providing increased global access. Moreover, we must consider that CF is characterized by remarkable allelic heterogeneity. Many patients cannot yet benefit from these treatments, as in the cases of patients carrying rare mutations still missing an approved treatment and unable to be included in clinical trials due to the rarity of their mutations. Indeed, traditional randomized trials would require sample sizes that exceed the entire eligible population. Theratyping procedures by means of in vitro predictive models can facilitate personalized medicine approaches to move therapy forward for all people with CF. Despite these efforts, some CF variants will remain difficult to rescue by “classical” CFTR modulators, and there is the need to develop gene-based therapies able to replace or edit the CFTR gene. Alternative approaches focused on the restoration of epithelial homeostasis by targeting proteins other than CFTR could also constitute mutation-agnostic therapies useful for all the patients regardless their genotypes. This topic on "Cystic Fibrosis" aims to gather reviews and original articles focused on novel, promising therapeutic approaches for this devastating disease at basic, translational and clinical levels, to provide expert insights and perspectives on advances in the field.
Dr. Nicoletta Pedemonte
Dr. Miqueias Lopes Pacheco
Dr. Vito Terlizzi
Dr. Paolo Scudieri
Dr. Fabio Bertozzi
Topic Editors
Keywords
- CFTR
- modulators
- gene therapy
- CRMS/CFSPID
- neonatal screening
- clinical outcomes
- lung transplantation
- CF microbiology
- personalized medicine
- alternative chloride channels
- proteostasis
- inflammation
- epithelium
- chloride secretion
- drug discovery
Participating Journals
Journal Name | Impact Factor | CiteScore | Launched Year | First Decision (median) | APC |
---|---|---|---|---|---|
![]()
Cells
|
5.1 | 9.9 | 2012 | 17 Days | CHF 2700 |
![]()
International Journal of Molecular Sciences
|
4.9 | 8.1 | 2000 | 16.8 Days | CHF 2900 |
![]()
Journal of Clinical Medicine
|
3.0 | 5.7 | 2012 | 16 Days | CHF 2600 |
![]()
Journal of Personalized Medicine
|
- | 4.1 | 2011 | 17.4 Days | CHF 2600 |
![]()
Pharmaceutics
|
4.9 | 7.9 | 2009 | 15.5 Days | CHF 2900 |
Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.
MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:
- Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
- Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
- Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
- Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
- Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.